Detection of factors related to treatment reduction in docetaxel and ramucirumab for non-small cell lung cancer treatment

Treatment using docetaxel (DOC) and ramucirumab (RAM) is an effective regimen in second or later line advanced non-small cell lung carcinoma (NSCLC) treatment. However, it induces severe adverse effects, resulting in treatment reduction such as dose reduction and/or discontinuation. This study aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Yoshitaka, Tamaki, Shinya, Hirate, Daisuke, Takada, Shinya, Takahashi, Kenta, Takekuma, Yoh, Sakakibara-Konishi, Jun, Shimizu, Yasushi, Kinoshita, Ichiro, Sugawara, Mitsuru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636055/
https://www.ncbi.nlm.nih.gov/pubmed/37945672
http://dx.doi.org/10.1038/s41598-023-46775-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636055/
https://www.ncbi.nlm.nih.gov/pubmed/37945672
http://dx.doi.org/10.1038/s41598-023-46775-9

Ejemplares similares